Prosecution Insights
Last updated: November 20, 2026
Application No. 19/061,415

Modified Monocytes/Macrophage Expressing Chimeric Antigen Receptors and Uses Thereof

Non-Final OA §102§103§112§DOUBLEPATENT
Filed
Feb 24, 2025
Priority
Jul 28, 2015 — provisional 62/197,675 +5 more
Examiner
BURKHART, MICHAEL D
Art Unit
1638
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
The Trustees of the University of Pennsylvania
OA Round
2 (Non-Final)
62%
Grant Probability
Moderate
2-3
OA Rounds
1y 7m
Est. Remaining
74%
With Interview

Examiner Intelligence

Grants 62% of resolved cases
62%
Career Allowance Rate
531 granted / 850 resolved
+2.5% vs TC avg
Moderate +12% lift
Without
With
+11.8%
Interview Lift
resolved cases with interview
Typical timeline
3y 4m
Avg Prosecution
35 currently pending
Career history
890
Total Applications
across all art units

Statute-Specific Performance

§101
5.1%
-34.9% vs TC avg
§103
28.4%
-11.6% vs TC avg
§102
19.2%
-20.8% vs TC avg
§112
26.4%
-13.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 850 resolved cases

Office Action

§102 §103 §112 §DOUBLEPATENT
DETAILED ACTION *** The Office Action mailed 10/5/2026 is vacated in favor of the instant Office Action in light of entry of the claim amendments dated 9/30/2025. *** Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claim 18 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 18 recites the limitation "the monocyte, macrophage or dendritic cell" in line 2. There is insufficient antecedent basis for this limitation in the claim. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claim(s) 1, 3-10, 12, 15-19, 21, 23 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Shiku et al (WO 2013/051718, April 2013, reference below to the English language equivalent cited by applicants, US 2014/0242701). Claim(s) 1, 3-10, 12, 15-19, 21, 23 is/are rejected under 35 U.S.C. 102(a)(2) as being anticipated by Shiku et al (US 2014/0242701, of record). Shiku et al teach macrophages transfected with a nucleic acid encoding a CAR (comprising the recited domains) with effector functions such as cytokine secretion (¶’s [0028], [0054], [0063], [0082]-[0090], Fig. 2). The effector activity, e.g. cytokine expression, may remain after exposure to said cytokines which are considered “suppressive” as they suppress target cells (Figs 19, 20, Example 12). The CAR may comprise an scFv (¶[0055]), a CD28 transmembrane domain (¶[0070]), dual signaling domains (¶’s [0064]), [0068], Fig. 2), a CD3 zeta domain ([0068]), a CD19 specific binding domain (¶[0060]), and be specific for cells expressing an antigen (¶’s [0004], [0054]). The cells may further comprise “synthetic” or “organic” molecules (¶’s [0080], [0085]). The cells are intended as therapeutics and thus are considered pharmaceuticals in a carrier which are administered for diseases such as cancer and tumors (¶ [0091]). Regarding claim 9, cytokine secretion is an M1 phenotype. The cells may comprise CD80 (¶[0070]). The cells are used to treat disease via antigen recognition on target cells (¶ [0091]). The cells can be prepared using viral vectors or electroporation (¶’s [0082]-[0085]). Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 1, 3-12, 15-19, 21, 23, 24 is/are rejected under 35 U.S.C. 103 as being unpatentable over Shiku et al (WO 2013/051718, April 2013, reference below to the English language equivalent cited by applicants, US 2014/0242701) in view of Weiskopf et al (Science, 2013, cited by applicants). The teachings of Shiku et al are as above and applied as before. Shiku et al do not teach inhibition of CD47 or SIRP activity. Weiskopf et al teaches the use of SIRPvariants and anti-CD47/SIRP antibodies to inhibit the activity of these molecules to improve antibody-mediated phagocytic effect of macrophages in immunotherapy protocols. The claimed cells and methods are essentially disclosed by Shiku et al with the exception of the inhibition of CD47 or SIRP limitation. The ordinary skilled artisan, seeking a method to prepare CAR-expressing macrophages, would have been motivated to use the CD47/SIRP inhibitors of Weiskopf et al because they are taught to be a well-known means for overcoming tumor immunity to antibody-mediated immunotherapy such as CARs. It would have been obvious for the skilled artisan to do this because of the known benefit of improving CAR therapy as taught by Shiku and Weiskopf et al. Given the teachings of the cited references and the level of skill of the ordinary skilled artisan at the time of applicants’ invention, it must be considered, absent evidence to the contrary, that the ordinary skilled artisan would have had a reasonable expectation of success in practicing the claimed invention. Claims 1, 3-10, 12, 15-21, 23, 24 is/are rejected under 35 U.S.C. 103 as being unpatentable over Shiku et al (WO 2013/051718, April 2013, reference below to the English language equivalent cited by applicants, US 2014/0242701) in view of Wang et al et al (US 9,777,064, e.f.d. 3/7/2015). The teachings of Shiku et al are as above and applied as before. Although Shiku et al teach electroporation of nucleic acids, Shiku et al do not electroporation of mRNA. Wang et al teach the electroporation of T cells with CAR-encoding nucleic acids, such as mRNA. See col. 45, lines 35-60, col. 47 line 63- col. 48; col. 55, lines 45-55. The claimed cells and methods are essentially disclosed by Shiku et al with the exception of the mRNA limitation. The ordinary skilled artisan, seeking a method to prepare CAR-expressing macrophages, would have been motivated to use the mRNA electroporation of Wang et al because it is taught to be an effective technique for introducing nucleic acids such as mRNA into cells. It would have been obvious for the skilled artisan to do this because of the known benefit of generating CAR T cells as taught by Shiku and Wang et al. Given the teachings of the cited references and the level of skill of the ordinary skilled artisan at the time of applicants’ invention, it must be considered, absent evidence to the contrary, that the ordinary skilled artisan would have had a reasonable expectation of success in practicing the claimed invention. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 1, 3-12, 15-21, 23, 24 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-28 of U.S. Patent No. 11,034,749. The ‘749 patent claims CAR-modified monocytes/macrophages and methods of treatment and making such cells, wherein the CAR comprises the domains recited by the instant claims. The only significant difference from the instant claims is the ‘749 cells include an Ad5f35 component. Claims 1, 3-10, 12, 15-17 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-3, 5, 7, 11, 12, 13 of U.S. Patent No. 11,306,133. The ‘133 patent claims CAR-modified monocytes/macrophages and a pharmaceutical composition, wherein the CAR comprises the domains recited by the instant claims. The only significant difference from the instant claims is the ‘133 cells include an Ad5f35 component and recite the specific antibodies of instant claim 4. Claims 1, 3-12, 15-21, 23, 24 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-14, 16-27 of U.S. Patent No. 11,306,134. The ‘134 patent claims CAR-modified monocytes/macrophages and methods of treatment and making such cells, wherein the CAR comprises the domains recited by the instant claims. The only significant difference from the instant claims is that the ‘134 cells include a lentiviral component and possess effector activity. Claims 1, 3-12, 15-21, 23, 24 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-24 of U.S. Patent No. 11,319,358. The ‘358 patent claims CAR-modified monocytes/macrophages and methods of treatment and making such cells, wherein the CAR comprises the domains recited by the instant claims. The only significant difference from the instant claims is the ‘358 cells include CAR expression and viability percentages. Claims 1, 3-12, 15-21, 23, 24 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-7, 9-14, 16-25, 27-30 of U.S. Patent No. 11,332,511. The ‘511 patent claims CAR-modified monocytes/macrophages (CD14+/CD11b+ cells are monocytes/macrophages) and methods of treatment and making such cells, wherein the CAR comprises the domains recited by the instant claims. The only significant difference from the instant claims is the ‘511 cells are CD14+/CD11b+ (i.e. monocyte/macrophages) and are directed to pharmaceutical compositions. Claims 1, 3-12, 15-19, 23, 24 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1, 4-17 of U.S. Patent No. 11,359,002. The ‘002 patent claims CAR-modified monocytes/macrophages and methods of treatment and making such cells, wherein the CAR comprises the domains recited by the instant claims. The only significant difference from the instant claims is the ‘002 cells have an upregulated M1 marker or a downregulated M2 marker. Claims 1, 3-12, 15-19, 23, 24 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1, 3, 4, 6-16, 19-24 of U.S. Patent No. 11,498,954. The ‘954 patent claims CAR-modified monocytes/macrophages and methods of treatment and making such cells, wherein the CAR comprises the domains recited by the instant claims. The only significant difference from the instant claims is the ‘954 cells have reduced SIRPalpha activity. Claims 1, 3-12, 15-21, 23, 24 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1, 3-13, 15-17, 19-29 of U.S. Patent No. 11,407,805. The ‘805 patent claims CAR-modified monocytes/macrophages and methods of treatment and making such cells, wherein the CAR comprises the domains recited by the instant claims. The only significant difference from the instant claims is the ‘805 cells have effector activity or an M1 phenotype. Conclusion No claim is allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michael Burkhart whose telephone number is (571)272-2915. The examiner can normally be reached M-F 8-5. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Tracy Vivlemore can be reached at 571 272-2914. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /MICHAEL D BURKHART/Primary Examiner, Art Unit 1638
Read full office action

Prosecution Timeline

Feb 24, 2025
Application Filed
Oct 05, 2026
Non-Final Rejection mailed — §102, §103, §112
Nov 06, 2026
Non-Final Rejection mailed — §102, §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12799182
CIRCULAR RNA COMPOSITIONS AND METHODS
3y 11m to grant Granted Nov 17, 2026
Patent 12799168
SIGNAL SEQUENCE THAT INDUCES PROTEIN SECRETION IN INTESTINAL MICROBIOME
3y 1m to grant Granted Nov 17, 2026
Patent 12781197
METHODS AND COMPOSITIONS FOR THE PURIFICATION OF ADENO-ASSOCIATED VIRUS
4y 0m to grant Granted Nov 03, 2026
Patent 12774317
HUMAN APPLICATION OF ENGINEERED CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELLS
3y 1m to grant Granted Oct 27, 2026
Patent 12754124
Hematological Parameter for Viral Infection
3y 11m to grant Granted Oct 06, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

2-3
Expected OA Rounds
62%
Grant Probability
74%
With Interview (+11.8%)
3y 4m (~1y 7m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 850 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month